Home World News Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic... World News Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 501 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine September 22, 2022 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never... August 8, 2019 Lucky 13-A Male Breast Cancer Story October 20, 2021 Can the New “Omics” on the Block Find Liver Cancer in... May 15, 2023 Load more HOT NEWS 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ Connecting and Celebrating
